Cybin Inc.(CYBN)Earnings, Financials & Key Ratios

CYBN•AMEX

$6.09

Price updated Jun 20, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryNeuroscience and Psychiatry Therapies

AboutCybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.Show more

Revenue$0
EBITDA-$143M-81.6%
Net Income-$113M-44.9%
EPS (Diluted)-0.61+93.5%
ROE-42.76%-0.8%

CYBN Price & Volume

Cybin Inc. (CYBN) stock price & volume — 10-year historical chart

Loading chart...

Persistent Clinical Burn Challenges Long-Term Solvency

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Mixed

Profitability:Negative

Financial:Adequate

Cash Flow:Burning

Primary Risk:Clinical trial regulatory failure

Key Thesis Takeaways

Cybin remains in a high-risk, pre-revenue development phase, characterized by significant quarterly operating losses that peaked at $58.3 million in 2025Q2.
While the company maintains a cash position of $118.7 million as of 2026Q1, the emergence of $44.5 million in debt and a cumulative deficit of $266.1 million underscore the intense capital requirements needed to navigate an increasingly stringent regulatory environment.
Investors should monitor the company's ability to achieve clinical milestones without further dilutive equity financing or excessive reliance on non-cash share-based compensation, which reached $33.5 million in a single quarter.

Verdict Logic

the company's persistent cash burn, evidenced by a $29.8 million free cash flow outflow in 2026Q1, combined with a deepening retained earnings deficit of $266.1 million, suggests significant ongoing financial risk.

CYBN Growth Metrics

Cybin Inc. (CYBN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-

5 Years-

3 Years-

TTM-

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM-56.81%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM-921.18%

Return on Capital

10 Years-340.77%

5 Years-489.46%

3 Years-53.34%

Last Year-54.11%

CYBN Recent Earnings

Cybin Inc. (CYBN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 3/12 qtrs (27%)

Q1 2026Latest

Feb 9, 2026

Metric

Actual

Est

EPS

$0.38+28.3%

$0.53

Rev

—

Q4 2025

Nov 13, 2025

Metric

Actual

Est

EPS

$1.39-87.8%

$0.74

Rev

—

Q3 2025

Aug 13, 2025

Metric

Actual

Est

EPS

$1.10-115.7%

$0.51

Rev

—

Q3 2025

Jun 30, 2025

Metric

Actual

Est

EPS

$1.02-100.0%

$0.51

Rev

—

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q1 2026Latest	Feb 9, 2026	$0.38vs $0.53+28.3%	—
Q4 2025	Nov 13, 2025	$1.39vs $0.74-87.8%	—
Q3 2025	Aug 13, 2025	$1.10vs $0.51-115.7%	—
Q3 2025	Jun 30, 2025	$1.02vs $0.51-100.0%	—

Based on last 12 quarters of dataView full earnings history →

Latest CYBN News

Recent stock market news and headlines for Cybin Inc. (CYBN)

Seeking Alpha·Jun 27, 2026

Cybin: A Speculative Bet On Their Pivotal Depression Readout

Cybin operates as Helus Pharma, which is a clinical-stage biotech built around deuterated serotonergic therapies for depression and anxiety. I believe their main value driver is HLP003, which will report in Q4 2026 its Phase 3 APPROACH readout. HELP also recently raised funds in June 2026, and they don't have financial debt. So, they should have enough resources to reach this important milestone later this year.

Peers Comparison

Key metrics vs top competitors for Cybin Inc. (CYBN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
CYBNCybin Inc.Current	$6.09	$303.86M	-13.66	—	—	-42.76%	—
CMPSCOMPASS Pathways plc	$12.99	$1.25B	-4.22	—	—	-151.02%	—
MNMDMind Medicine (MindMed) Inc.	$20.69	$2.04B	-10.04	—	—	-102.48%	—
ATAIAtai Beckley N.V	$5.19	$1.91B	-1.78	1227.6%	-19019.44%	-366.21%	—
SILOSilo Pharma, Inc.	$5.66	$5.12M	-0.75	—	-6717.4%	-88.41%	—
HALOHalozyme Therapeutics, Inc.	$81.57	$9.68B	31.86	37.55%	23.13%	126.27%	—

Compare CYBN vs Peers

Cybin Inc. (CYBN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs CMPS

Most directly comparable listed peer for CYBN.

Scale Benchmark

vs AXSM

Larger-name benchmark to compare CYBN against a more recognizable public peer.

Peer Set

Compare Top 5

vs CMPS, MNMD, ATAI, SILO

Get notified when CYBN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

CYBN Frequently Asked Questions

Cybin Inc. (CYBN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is CYBN profitable?

Cybin Inc. (CYBN) reported a net loss of $122.9M for fiscal year 2025.

Dividend & Returns

What is CYBN's return on equity?

Cybin Inc. (CYBN) has a return on equity (ROE) of -42.8%. Negative ROE indicates the company is unprofitable.

What is Cybin Inc.'s free cash flow?

Cybin Inc. (CYBN) had negative free cash flow of $105.6M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CYBN back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q1 2026Latest

Feb 9, 2026

$0.38vs $0.53+28.3%

—

Q4 2025

Nov 13, 2025

$1.39vs $0.74-87.8%

—

Q3 2025

Aug 13, 2025

$1.10vs $0.51-115.7%

—

Q3 2025

Jun 30, 2025

$1.02vs $0.51-100.0%

—

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

CYBNCybin Inc.Current

$6.09

$303.86M

-13.66

—

-42.76%

—

CMPSCOMPASS Pathways plc

$12.99

$1.25B

-4.22

—

-151.02%

—

MNMDMind Medicine (MindMed) Inc.

$20.69

$2.04B

-10.04

—

-102.48%

—

ATAIAtai Beckley N.V

$5.19

$1.91B

-1.78

1227.6%

-19019.44%

-366.21%

—

SILOSilo Pharma, Inc.

$5.66

$5.12M

-0.75

—

-6717.4%

-88.41%

—

HALOHalozyme Therapeutics, Inc.

$81.57

$9.68B

31.86

37.55%

23.13%

126.27%

—